ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

FT1

Its studies are mostly in Short Bowel Syndrome · Diarrhea, led by Chongqing Peg-Bio Biopharm.

Furthest: phase 2, since Jul 3, 20262 company-led studies, 1 open or runningNext primary completion: Apr 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Peg-Bio Biopharm21 open or runningphase 2since Jul 3, 2026Sep 20, 2024Apr 15, 2027phase 2 · NCT07704047

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2024First study: phase 1 study in Diarrhea Caused by Drug (Disorder)First studyNCT06610487 · 60 enrolled · China
  2. Jul 3, 2026Phase 2 study in Short Bowel SyndromePhase 2 reachedNCT07704047 · 8 planned · China

Ahead

  1. Apr 15, 2027Primary completion: phase 2 study in Short Bowel SyndromeNCT07704047

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704047Short Bowel Syndrome · China2RecruitingApr 15, 20278
NCT06610487Diarrhea Caused by Drug (Disorder) · China1CompletedAug 8, 202560

How it is read

Names in the registry

  • “FT1”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.